Cerus And 2 Other US Penny Stocks With Promising Potential

The U.S. stock market has recently experienced a surge, with major indexes like the Dow Jones and Nasdaq showing significant gains, driven by strong performances in technology stocks and a notable rise in Bitcoin. Amidst this backdrop, penny stocks continue to capture investor interest as they offer unique opportunities for growth at lower price points. Though often associated with smaller or newer companies, these stocks can present substantial potential when backed by solid financials and sound business strategies.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8224	$5.97M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.00	$1.76B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$102.23M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.63	$10.89M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.3264	$12.01M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.74	$47.54M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.40	$24.83M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.9846	$88.55M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.54	$377.99M	★★★★☆☆

Click here to see the full list of 719 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Cerus (NasdaqGM:CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $312.00 million.

Operations: The company generates $176.23 million in revenue from its Blood Safety segment.

Market Cap: $312M

Cerus Corporation, with a market cap of US$312 million, generates US$176.23 million in revenue from its Blood Safety segment. Despite being unprofitable, the company has reduced losses over the past five years at 17.6% annually and maintains a sufficient cash runway for more than three years based on current free cash flow. Recent developments include raising its 2024 revenue guidance and entering into an extended supply agreement with Porex Corporation effective January 2025. However, shareholders have faced dilution over the past year as total shares outstanding increased by 2.5%.

• Navigate through the intricacies of Cerus with our comprehensive balance sheet health report here.
• Learn about Cerus' future growth trajectory here.

Amylyx Pharmaceuticals (NasdaqGS:AMLX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing treatments for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, with a market cap of approximately $282.54 million.

Operations: The company generated $196.49 million in revenue from its efforts in researching and developing therapeutics for neurodegenerative disorders.

Market Cap: $282.54M

Amylyx Pharmaceuticals, with a market cap of US$282.54 million, focuses on treatments for neurodegenerative diseases, generating US$196.49 million in revenue. Despite being unprofitable and having a negative return on equity of -132.24%, the company maintains sufficient cash runway for over a year and is debt-free. Recent developments include appointing Dan Monahan as Chief Commercial Officer to lead commercialization efforts, particularly for avexitide's potential approval. Collaborations like the one with Gubra A/S aim to advance novel therapeutics, while ongoing clinical trials such as LUCIDITY highlight its commitment to addressing unmet medical needs in post-bariatric hypoglycemia treatment.

• Click to explore a detailed breakdown of our findings in Amylyx Pharmaceuticals' financial health report.
• Gain insights into Amylyx Pharmaceuticals' future direction by reviewing our growth report.

Dakota Gold (NYSEAM:DC)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dakota Gold Corp. is involved in the acquisition, exploration, and development of mineral properties in the United States with a market cap of $222.86 million.

Operations: Dakota Gold Corp. does not report distinct revenue segments as it focuses on acquiring, exploring, and developing mineral properties in the United States.

Market Cap: $222.86M

Dakota Gold Corp., with a market cap of US$222.86 million, remains pre-revenue as it focuses on mineral exploration and development. The company is debt-free but has a limited cash runway of less than a year at current free cash flow rates. Recent drilling at the Maitland Gold Project has significantly extended known mineralization, revealing high-grade gold intercepts analogous to the historic Homestake Mine. Leadership changes include Robert Quartermain's appointment as CEO, bringing experience from Pretium Resources. Despite shareholder dilution and ongoing losses, Dakota Gold is advancing its Richmond Hill project towards feasibility studies in 2025.

• Click here to discover the nuances of Dakota Gold with our detailed analytical financial health report.
• Explore historical data to track Dakota Gold's performance over time in our past results report.

Key Takeaways

• Reveal the 719 hidden gems among our US Penny Stocks screener with a single click here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com